These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
539 related articles for article (PubMed ID: 26288822)
1. Serum DHCR24 Auto-antibody as a new Biomarker for Progression of Hepatitis C. Ezzikouri S; Kimura K; Sunagozaka H; Kaneko S; Inoue K; Nishimura T; Hishima T; Kohara M; Tsukiyama-Kohara K EBioMedicine; 2015 Jun; 2(6):604-12. PubMed ID: 26288822 [TBL] [Abstract][Full Text] [Related]
2. 3β-hydroxysterol δ24-reductase on the surface of hepatitis C virus-related hepatocellular carcinoma cells can be a target for molecular targeting therapy. Saito M; Takano T; Nishimura T; Kohara M; Tsukiyama-Kohara K PLoS One; 2015; 10(4):e0124197. PubMed ID: 25875901 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of prothrombin induced by vitamin K absence, macrophage migration inhibitory factor and Golgi protein-73 versus alpha fetoprotein for hepatocellular carcinoma diagnosis and surveillance. Ismail MM; Morsi HK; Abdulateef NA; Noaman MK; Abou El-Ella GA Scand J Clin Lab Invest; 2017 May; 77(3):175-183. PubMed ID: 28276727 [TBL] [Abstract][Full Text] [Related]
4. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group. Ishii M; Gama H; Chida N; Ueno Y; Shinzawa H; Takagi T; Toyota T; Takahashi T; Kasukawa R Am J Gastroenterol; 2000 Apr; 95(4):1036-40. PubMed ID: 10763956 [TBL] [Abstract][Full Text] [Related]
5. Could serotonin be a potential marker for hepatocellular carcinoma? A prospective single-center observational study. Abdel-Razik A; Elhelaly R; Elzehery R; El-Diasty A; Abed S; Elhammady D; Tawfik A Eur J Gastroenterol Hepatol; 2016 May; 28(5):599-605. PubMed ID: 26741637 [TBL] [Abstract][Full Text] [Related]
6. Serum anti-Ku86 is a potential biomarker for early detection of hepatitis C virus-related hepatocellular carcinoma. Nomura F; Sogawa K; Noda K; Seimiya M; Matsushita K; Miura T; Tomonaga T; Yoshitomi H; Imazeki F; Takizawa H; Mogushi K; Miyazaki M; Yokosuka O Biochem Biophys Res Commun; 2012 May; 421(4):837-43. PubMed ID: 22554520 [TBL] [Abstract][Full Text] [Related]
7. A Potential Serum Higashi M; Yoshimura T; Usui N; Kano Y; Deguchi A; Tanabe K; Uchimura Y; Kuriyama S; Suzuki Y; Masaki T; Ikenaka K Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255418 [TBL] [Abstract][Full Text] [Related]
8. Diagnostic performance of tumor markers AFP and PIVKA-II in Chinese hepatocellular carcinoma patients. Huang S; Jiang F; Wang Y; Yu Y; Ren S; Wang X; Yin P; Lou J Tumour Biol; 2017 Jun; 39(6):1010428317705763. PubMed ID: 28621228 [TBL] [Abstract][Full Text] [Related]
9. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients. Lim TS; Kim DY; Han KH; Kim HS; Shin SH; Jung KS; Kim BK; Kim SU; Park JY; Ahn SH Scand J Gastroenterol; 2016 Mar; 51(3):344-53. PubMed ID: 26340708 [TBL] [Abstract][Full Text] [Related]
10. Development of Serum DHCR24 Antibody as a Marker for Hepatocellular Carcinoma: The End of the Beginning. Chan SL; Chan AW EBioMedicine; 2015 Jun; 2(6):497-8. PubMed ID: 26288814 [No Abstract] [Full Text] [Related]
11. Diagnostic value of the γ-glutamyltransferase and alanine transaminase ratio, alpha-fetoprotein, and protein induced by vitamin K absence or antagonist II in hepatitis B virus-related hepatocellular carcinoma. Wang G; Lu X; Du Q; Zhang G; Wang D; Wang Q; Guo X Sci Rep; 2020 Aug; 10(1):13519. PubMed ID: 32782270 [TBL] [Abstract][Full Text] [Related]
12. [Serum anti-Ku86: a potential biomarker for early detection of hepatocellular carcinoma]. Chu L; Zhang X; Wang G; Zhou W; Du Z; Liu A; Zhao H Zhonghua Zhong Liu Za Zhi; 2014 Feb; 36(2):123-7. PubMed ID: 24796461 [TBL] [Abstract][Full Text] [Related]
13. Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA. Wu J; Xiang Z; Bai L; He L; Tan L; Hu M; Ren Y Cancer Biomark; 2018; 23(2):235-242. PubMed ID: 30103302 [TBL] [Abstract][Full Text] [Related]
14. Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma. Seo SI; Kim HS; Kim WJ; Shin WG; Kim DJ; Kim KH; Jang MK; Lee JH; Kim JS; Kim HY; Kim DJ; Lee MS; Park CK World J Gastroenterol; 2015 Apr; 21(13):3928-35. PubMed ID: 25852278 [TBL] [Abstract][Full Text] [Related]
15. Genomic polymorphisms in 3β-hydroxysterol Δ24-reductase promoter sequences. Salem NE; Saito M; Kasama Y; Ozawa M; Kawabata T; Harada S; Suda H; Asonuma K; El-Gohary A; Tsukiyama-Kohara K Microbiol Immunol; 2013 Mar; 57(3):179-84. PubMed ID: 23277918 [TBL] [Abstract][Full Text] [Related]
16. Diagnostic Accuracy of PIVKA-II, Alpha-Fetoprotein and a Combination of both in Diagnosis of Hepatocellular Carcinoma in Patients Affected by Chronic HCV Infection. Gentile I; Buonomo AR; Scotto R; Zappulo E; Carriero C; Piccirillo M; Izzo F; Rizzo M; Cerasuolo D; Borgia G; Cavalcanti E In Vivo; 2017; 31(4):695-700. PubMed ID: 28652441 [TBL] [Abstract][Full Text] [Related]
17. Role of serum prothrombin induced by vitamin K absence or antagonist-II in the early detection of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Yoon YJ; Han KH; Kim DY Scand J Gastroenterol; 2009; 44(7):861-6. PubMed ID: 19391065 [TBL] [Abstract][Full Text] [Related]
18. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961 [TBL] [Abstract][Full Text] [Related]
19. Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion. Poté N; Cauchy F; Albuquerque M; Voitot H; Belghiti J; Castera L; Puy H; Bedossa P; Paradis V J Hepatol; 2015 Apr; 62(4):848-54. PubMed ID: 25450201 [TBL] [Abstract][Full Text] [Related]
20. Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II. Caviglia GP; Abate ML; Gaia S; Petrini E; Bosco C; Olivero A; Rosso C; Ciancio A; Pellicano R; Saracco GM; Rizzetto M; Smedile A Panminerva Med; 2017 Dec; 59(4):283-289. PubMed ID: 28650134 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]